A two‑microRNA signature as a potential biomarker for early gastric cancer

Zheng,Guorong; Xiong,Yimin; Xu,Weitian; Wang,Yan; Chen,Fang; Wang,Zhigang; Yan,Zhi

doi:10.3892/ol.2014.1797

A two‑microRNA signature as a potential biomarker for early gastric cancer

Authors:
- Guorong Zheng
- Yimin Xiong
- Weitian Xu
- Yan Wang
- Fang Chen
- Zhigang Wang
- Zhi Yan
View Affiliations

Affiliations: Department of Digestive Diseases, Wuhan General Hospital of Guangzhou Command, Wuchang, Wuhan 430070, P.R. China, Department of Medical Laboratory, Wuhan General Hospital of Guangzhou Command, Wuchang, Wuhan 430070, P.R. China, Department of Oncology, Wuhan General Hospital of Guangzhou Command, Wuchang, Wuhan 430070, P.R. China
Published online on: January 15, 2014 https://doi.org/10.3892/ol.2014.1797
Pages: 679-684

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most common malignant tumors worldwide. No fundamental improvements in the five‑year survival rates of patients with GC have been reported due to a low early diagnosis rate. Therefore, the identification of novel biomarkers is urgently required for an early diagnosis of GC. A total of 86 patients were selected for the present study, including 44 patients with early stage GC (T1‑T2 according to TNM staging criteria) and 42 normal gastric mucosa samples from non‑cancer patients as controls. A total of 18 samples were used for the microRNA (miRNA) microarray experiments, including nine early GC and nine normal gastric mucosa samples. Bioinformatics algorithms, significant analysis of microarray (SAM), top scoring pair (TSP) and statistical receiver operating characteristic curves were used to identify the best signatures. Finally, quantitative PCR was used to validate the candidate biomarkers for early gastric cancer in the test samples (35 cancer and 33 normal samples). Using the SAM algorithm, 14 differential miRNAs were selected as candidate biomarkers. Using the TSP algorithm, hsa‑miR‑196a and hsa‑miR‑148a were obtained as a signature to differentiate between the early GC and normal samples. A coincidental result was observed in the test samples. hsa‑miR‑196a was upregulated and hsa‑miR‑148a was downregulated in the early GC samples. hsa‑miR‑196a and hsa‑miR‑148a have the potential to serve as candidate biomarkers for early GC.

View Figures

View References

1	Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol. 12:17–20. 2006.
2	Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
3	Shiozawa N, Kodama M, Chida T, Arakawa A, Tur GE and Koyama K: Recurrent death among early gastric cancer patients: 20 years’ experience. Hepatogastroenterology. 41:244–247. 1994.
4	Kim JP, Hur YS and Yang HK: Lymph node metastasis as a significant prognostic factor in early gastric cancer: analysis of 1,136 early gastric cancers. Ann Surg Oncol. 2:308–313. 1995. View Article : Google Scholar
5	Degiuli M and Calvo F: Survival of early gastric cancer in a specialized European center. Which lymphadenectomy is necessary? World J Surg. 30:2193–2203. 2006. View Article : Google Scholar
6	Smith JW, Shiu MH, Kelsey L and Brennan MF: Morbidity of radical lymphadenectomy in the curative resection of gastric cancer. Arch Surg. 126:1469–1473. 1991. View Article : Google Scholar : PubMed/NCBI
7	Crispi S, Calogero RA, Santini M, et al: Global gene expression profiling of human pleural mesotheliomas: identification of matrix metalloproteinase 14 (MMP-14) as potential tumour target. PLoS One. 4:e70162009. View Article : Google Scholar
8	Guo RF, Zang SZ, Fang JY, et al: Identification of biomarkers for early detection in gastric cancer and its clinical biological significance. Beijing Da Xue Xue Bao. 41:353–360. 2009.(In Chinese).
9	Fèvre-Montange M, Champier J, Durand A, et al: Microarray gene expression profiling in meningiomas: differential expression according to grade or histopathological subtype. Int J Oncol. 35:1395–1407. 2009.
10	Yoshihara K, Tajima A, Komata D, et al: Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumour progression and prognosis. Cancer Sci. 100:1421–1428. 2009. View Article : Google Scholar
11	Lau SK, Boutros PC, Pintilie M, et al: Three-gene prognostic classifier for early-stage non small-cell lung cancer. J Clin Oncol. 25:5562–5569. 2007. View Article : Google Scholar : PubMed/NCBI
12	Zervakis M, Blazadonakis ME, Tsiliki G, et al: Outcome prediction based on microarray analysis: a critical perspective on methods. BMC Bioinformatics. 10:532009. View Article : Google Scholar : PubMed/NCBI
13	Yan Z, Xiong Y, Xu W, et al: Identification of hsa-miR-335 as a prognostic signature in gastric cancer. PLoS One. 7:e400372012. View Article : Google Scholar : PubMed/NCBI
14	Chen C, Ridzon DA, Broomer AJ, et al: Real time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
16	Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to transcriptional responses to ionizing radiation. Proc Natl Acad Sci USA. 98:5116–5121. 2001. View Article : Google Scholar : PubMed/NCBI
17	Tan AC, Naiman DQ, Xu L, et al: Simple decision rules for classifying human cancers from gene expression profiles. Bioinformatics. 21:3896–3904. 2005. View Article : Google Scholar : PubMed/NCBI
18	Liang RQ, Li W, Li Y, et al: An oligonucleotide microarray for microRNA expression analysis based on labeling RNA with quantum dot and nanogold probe. Nucl Acids Res. 33:e172005. View Article : Google Scholar : PubMed/NCBI
19	Price ND, Trent J, El-Naggar AK, et al: Highly accurate two-gene classifier for differentiating gastrointestinal stromal tumors and leiomyosarcomas. Proc Natl Acad Sci USA. 104:3414–3419. 2007. View Article : Google Scholar
20	Sun M, Liu XH, Li JH, et al: MiR-196a is upregulated in gastric cancer and promotes cell proliferation by downregulating p27(kip1). Mol Cancer Ther. 11:842–852. 2012. View Article : Google Scholar : PubMed/NCBI
21	Niinuma T, Suzuki H, Nojima M, et al: Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res. 72:1126–1136. 2012. View Article : Google Scholar : PubMed/NCBI
22	Schimanski CC, Frerichs K, Rahman F, et al: High miR-196a levels promote the oncogenic phenotype of colorectal cancer cells. World J Gastroenterol. 15:2089–2096. 2009. View Article : Google Scholar : PubMed/NCBI
23	Kong X, Du Y, Wang G, et al: Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 56:602–609. 2011. View Article : Google Scholar
24	Wang K, Li J, Guo H, et al: MiR-196a binding-site SNP regulates RAP1A expression contributing to esophageal squamous cell carcinoma risk and metastasis. Carcinogenesis. 33:2147–2154. 2012. View Article : Google Scholar : PubMed/NCBI
25	Tsai KW, Liao YL, Wu CW, et al: Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer. 51:394–401. 2012. View Article : Google Scholar : PubMed/NCBI
26	Christensen BC, Avissar-Whiting M, Ouellet LG, et al: Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin Cancer Res. 16:3713–3720. 2010. View Article : Google Scholar : PubMed/NCBI
27	Song YX, Yue ZY, Wang ZN, et al: MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer. 10:12011. View Article : Google Scholar : PubMed/NCBI
28	Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y and Xu HM: Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep. 27:447–454. 2012.PubMed/NCBI
29	Zheng B, Liang L, Wang C, et al: MicroRNA-148a suppresses tumor cell invasion and metastasis by downregulating ROCK1 in gastric cancer. Clin Cancer Res. 17:7574–83. 2011. View Article : Google Scholar : PubMed/NCBI
30	Schultz NA, Andersen KK, Roslind A, Willenbrock H, Wøjdemann M and Johansen JS: Prognostic microRNAs in cancer tissue from patients operated for pancreatic cancer - five microRNAs in a prognostic index. World J Surg. 36:2699–2707. 2012. View Article : Google Scholar
31	Takahashi M, Cuatrecasas M, Balaguer F, et al: The clinical significance of MiR-148a as a predictive biomarker in patients with advanced colorectalcancer. PLoS One. 7:e466842012. View Article : Google Scholar : PubMed/NCBI